EP Patent

EP1799659A1 — Compounds for nonsense suppression, and methods for their use

Assigned to PTC Therapeutics Inc · Expires 2007-06-27 · 19y expired

What this patent protects

The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to met…

USPTO Abstract

The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

Drugs covered by this patent

Patent Metadata

Patent number
EP1799659A1
Jurisdiction
EP
Classification
Expires
2007-06-27
Drug substance claim
No
Drug product claim
No
Assignee
PTC Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.